Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD I: Mirvetuximab Soravtansine vs Investigator's Choice in FRα-positive Advanced Ovarian Cancer
2015-004060-11Phase 2Completed
- Sponsor
- ImmunoGen
- Start
- Feb 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mirvetuximab soravtansine in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 1 more (2 arms), sponsored by ImmunoGen. Started Feb 2016; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)malignant peritoneal neoplasm
Beyond the preview
Go deeper on 2015-004060-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004060-11.